Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Drug Delivery and Translational Research

• Publication date

  2015-03-21

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s13346-015-0222-6PMID 25795051
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Old Wine in a New Bottle : Historical reflections on sport as a context for youth development

  2016cited by this paper
• Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?

  2014cited by this paper
• GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012

  2013cited by this paper
• Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

  2013cited by this paper
• PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells

  2012cited by this paper
• Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance

  2012cited by this paper
• Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer.

  2011cited by this paper
• Transplantable Syngeneic Rodent Tumors: Solid Tumors in Mice

  2011influential reference
• Liposomes as multicompartmental carriers for multidrug delivery in anticancer chemotherapy

  2011cited by this paper
• Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

  2011cited by this paper
• Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer

  2011cited by this paper
• Thermodynamic and kinetic stability of DSPE-PEG(2000) micelles in the presence of bovine serum albumin.

  2010cited by this paper
• Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: Implications on pharmacokinetics and drug toxicities.

  2009cited by this paper
• Effect of cholesterol on the release of amphotericin B from PEG-phospholipid micelles.

  2008cited by this paper
• Multi-target therapeutics: when the whole is greater than the sum of the parts.

  2007cited by this paper
• Optimizing combination chemotherapy by controlling drug ratios.

  2007cited by this paper
• The Riminophenazine Agents Clofazimine and B 669 Inhibit the Proliferation of Cancer Cell Lines in Vitro by Phospholipase Az-mediated Oxidative and Nonoxidative Mechanisms

  2007cited by this paper
• Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

  2006cited by this paper
• In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors.

  2006cited by this paper
• Novel formulations of taxanes: a review. Old wine in a new bottle?

  2006cited by this paper
• Lipid-core micelles for targeted drug delivery.

  2005cited by this paper
• The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations.

  2005cited by this paper
• Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs.

  2004cited by this paper
• Tetramethylpiperidine-Substituted Phenazines Inhibit the Proliferation of Intrinsically Multidrug Resistant Carcinoma Cell Lines

  2004cited by this paper
• Drug Resistance in Cancer: A Perspective

  2004cited by this paper
• Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.

  2003cited by this paper
• Polyethylene Glycol-Diacyllipid Micelles Demonstrate Increased Accumulation in Subcutaneous Tumors in Mice

  2002cited by this paper
• Diacyllipid-Polymer Micelles as Nanocarriers for Poorly Soluble Anticancer Drugs

  2002cited by this paper
• Tumor Models in Cancer Research

  2001cited by this paper
• Intracellular Levels of Two Cyclosporin Derivatives Valspodar (PSC 833) and Cyclosporin A Closely Associated with Multidrug Resistance‐modulating Activity in Sublines of Human Colorectal Adenocarcinoma HCT‐15

  2001cited by this paper
• Recent advances in the chemistry of taxol.

  2000cited by this paper
• Clofazimine and B4121 sensitize an intrinsically resistant human colon cancer cell line to P-glycoprotein substrates.

  2000cited by this paper
• A Phase II Evaluation of Clofazimine plus Doxorubicin in Advanced, Unresectable Primary Hepatocellular Carcinoma

  1999cited by this paper
• In vivo model systems in P-glycoprotein-mediated multidrug resistance.

  1998cited by this paper
• A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma.

  1998cited by this paper
• The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.

  1998cited by this paper
• Accumulation of Protein-Loaded Long-Circulating Micelles and Liposomes in Subcutaneous Lewis Lung Carcinoma in Mice

  1998cited by this paper
• Riminophenazine compounds: pharmacology and anti-neoplastic potential.

  1997cited by this paper
• Novel tetramethylpiperidine-substituted phenazines are potent inhibitors of P-glycoprotein activity in a multidrug resistant cancer cell line

  1997cited by this paper
• Anticancer Drug Development Guide

  1997cited by this paper
• Human Tumor Xenograft Models in NCI Drug Development

  1997cited by this paper
• In Vivo Methods for Screening and Preclinical Testing

  1997cited by this paper
• The riminophenazine agents clofazimine and B669 inhibit the proliferation of intrinsically multidrug resistant carcinoma cell lines.

  1996cited by this paper
• Chemosensitizing interactions of clofazimine and B669 with human K562 erythroleukaemia cells with varying levels of expression of P-glycoprotein.

  1996cited by this paper
• The riminophenazine agents clofazimine and B669 reverse acquired multidrug resistance in a human lung cancer cell line.

  1994cited by this paper
• Clofazimine alters the energy metabolism and inhibits the growth rate of a human lung‐cancer cell line in vitro and in vivo

  1994cited by this paper
• The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms.

  1993cited by this paper
• Evaluation of the antineoplastic activities of the riminophenazine agents clofazimine and b669 in tumor-bearing rats and mice.

  1993cited by this paper
• Clinical Pharmacokinetics of Clofazimine

  1989cited by this paper
• Clofazimine binding studies with deoxyribonucleic acid.

  1976cited by this paper
• Antimitochondrial activity of lampren in Saccharomyces cerevisiae.

  1973cited by this paper

• Development and validation of an RBP gene signature for prognosis prediction in colorectal cancer based on WGCNA

  2023cites this paper
• Molecular design of a pathogen activated, self-assembling mechanopharmaceutical device.

  2022cites this paper
• Optimization and Pharmacokinetic Evaluation of Synergistic Fenbendazole and Rapamycin Co-Encapsulated in Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles

  2021cites this paper
• A new therapeutic combination for osteosarcoma: Gemcitabine and Clofazimine co‐loaded liposomal formulation

  2019cites this paper
• Co-delivery of Docetaxel and Disulfonate Tetraphenyl Chlorin in One Nanoparticle Produces Strong Synergism between Chemo- and Photodynamic Therapy in Drug-Sensitive and -Resistant Cancer Cells.

  2018cites this paper
• Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line.

  2017cites this paper
• Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma

  2016cites this paper